Sino-Italian partnership to set new benchmark in global healthcare industry

The agreement between the Chinese giant KHB and the Italian companies Altergon & Technogenetics, is the starting point for creating an international in vitro diagnostics group that offers new global business opportunities.

Ambitious projects

Once again, Italian know-how is underpinning ambitious global projects, while Chinese multinationals say they are ready to enter highly' competitive and strategic sectors, such as in vitro diagnostics. Thanks to a project that was agreed last summer and promoted and coordinated by Salvatore Cincotti, Technogenetics and Altergon Italia's CEO, these two innovative Italian companies are preparing to contribute to scientific progress on a global scale. The Chinese giant KHB (Shanghai Kehua Bio-Engineering Co, Ltd) has acquired 100 percent of Technogenetics and the in vitro assets of Altergon Italia, helping in recent yearn to strengthen R&D activities in immunodiagnostics with important internationalization programs. Technogenetics is ail Italian center of excellence, situated in Lodi, with over 30 years.' experience in the diagnostic research and biotechnologies sector, focusing mainly on the autoimmunity, infectious diseases and molecular genetics markets. KHB, which is listed on the Shenzhen Stock Exchange, is one of the most important manufacturer of IVD reagents and instruments in China. This project, as part of KHB's commercial strategy, is viewed as the start of an expansion process towards new business opportunities in the European arid North American markets.